Selective Activation of Drugs by Redox Processes: NATO Science Series A:, cartea 198
Editat de GE ADAMS, A. Breccia, E. M. Fielden, P. Wardmanen Limba Engleză Paperback – 21 oct 2012
Din seria NATO Science Series A:
- 15% Preț: 643.29 lei
- 15% Preț: 641.89 lei
- 15% Preț: 664.63 lei
- Preț: 389.39 lei
- 5% Preț: 370.28 lei
- Preț: 389.77 lei
- 18% Preț: 1207.41 lei
- 5% Preț: 716.85 lei
- Preț: 404.85 lei
- 15% Preț: 636.09 lei
- 5% Preț: 362.03 lei
- Preț: 399.37 lei
- 5% Preț: 2118.28 lei
- Preț: 399.21 lei
- Preț: 388.44 lei
- 15% Preț: 650.50 lei
- Preț: 379.59 lei
- Preț: 385.25 lei
- Preț: 390.36 lei
- Preț: 393.18 lei
- 15% Preț: 665.09 lei
- Preț: 387.16 lei
- 18% Preț: 933.10 lei
- 15% Preț: 641.20 lei
- Preț: 393.93 lei
- Preț: 393.18 lei
- 15% Preț: 642.02 lei
- Preț: 386.77 lei
- Preț: 376.76 lei
- 5% Preț: 387.66 lei
- 5% Preț: 1392.73 lei
- 15% Preț: 638.17 lei
- Preț: 392.05 lei
- Preț: 379.22 lei
- 5% Preț: 378.35 lei
- Preț: 395.80 lei
- 15% Preț: 638.35 lei
- Preț: 385.99 lei
- 5% Preț: 368.85 lei
- Preț: 392.23 lei
- 5% Preț: 381.02 lei
- Preț: 392.60 lei
- 5% Preț: 725.61 lei
- 18% Preț: 1200.32 lei
- 5% Preț: 378.69 lei
- Preț: 413.33 lei
Preț: 370.48 lei
Preț vechi: 389.98 lei
-5% Nou
Puncte Express: 556
Preț estimativ în valută:
70.90€ • 73.65$ • 58.89£
70.90€ • 73.65$ • 58.89£
Carte tipărită la comandă
Livrare economică 03-17 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781461366799
ISBN-10: 1461366798
Pagini: 376
Ilustrații: XI, 361 p.
Dimensiuni: 178 x 254 x 20 mm
Greutate: 0.65 kg
Ediția:1990
Editura: Springer Us
Colecția Springer
Seria NATO Science Series A:
Locul publicării:New York, NY, United States
ISBN-10: 1461366798
Pagini: 376
Ilustrații: XI, 361 p.
Dimensiuni: 178 x 254 x 20 mm
Greutate: 0.65 kg
Ediția:1990
Editura: Springer Us
Colecția Springer
Seria NATO Science Series A:
Locul publicării:New York, NY, United States
Public țintă
ResearchCuprins
Characteristics of Hypoxic Cells that Enhance their Susceptibility to Chemical Injury.- Prediction and Measurement of Redox Properties of Drugs and Biomolecules.- Metal-Catalyzed Redox Processes in Biological Systems and Drug Activation.- Redox Systems Generated by Electro-chemical Oxidations and Reductions.- The Rôle of DNA Damage in the Bioreductive Action of 2-Nitroimidazoles.- Redox Properties of Radiation Induced Free Radicals.- Reduction of Bleomycin-Fe by Reductases and Active Oxygen Formation.- Redox Activation of Drugs by the Red Blood Cell Membrane.- Induction of Stress Proteins and Drug Resistance by Hypoxia and Applications of Magnetic Resonance Spectroscopy and Cryospectrophotometry for Detecting Hypoxia in Tumors.- Mechanisms of Activation of Mitomycin C and AZQ in Aerobic and Hypoxic Mammalian Cells.- Molecular Interactions and Biological Effects of the Products of Reduction of Nitroimidazoles.- Redox Activation of Benzotriazine N-oxides: Mechanisms and Potential as Anticancer Drugs.- Nitroacridines and Nitroquinolines as DNA-affinic Hypoxia-selective Cytotoxins.- Metabolic Effects of Hypoxic Cell Sensitizers.- Does Ro-03–8799 Concentration in Human Tumour Xenografts Predict Radiosensitization? Comparison with SR-2508.- Enzyme-directed Bioreductive Drug Development.- Improved Treatment of Tumours in vivo by Combining the Bioreductive Drug, RSU-1069, Hydralazine and Hyperthermia.- Assessment of Bioreductive Drug Toxicity in vitro and in Experimental Tumours in vivo.- Activity of Bioreductive Agents in Human and Rodent Tumor Cells.- The Control of Tumour Oxygenation in Mice: The Importance of Tumour Site.- Critical Events in the Toxicity of Redox Active Drugs.- The Reductive Activation of Nitroimidazoles; Modification by Oxygen and other Redox-activeMolecules in Cellular Systems.- Fluorescent Probes for Hypoxia: Chemical Aspects.- Toxicity of Metal Complexes with Radiosensitizing Properties.- Effects on DNA of Bioreducible Nitroimidazole and Benzotriazine Drugs.- Response of Repair and Reduction Deficient Mutants to Agents Requiring Bioreduction.- Bioreductive Drugs and Radiation: Pharmacokinetics and Clinical Trials of Etanidazole Radiosensitizer.- The Oncogenic Potential of Bioreductive Drugs.- Adduct Formation by 2-Nitroimidazole in Mammalian Cells: Optimization of Markers for Tissue Oxygenation.- Tumour Blood Flow and its Modulation: Implications for Bioreductive Drug Activity in vivo.- Poster Presentations.- Participants.